PMID- 35447227
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220614
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 246
DP  - 2022 Jun
TI  - Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: 
      Involvement of PI3K/AKT/mTOR signaling pathway.
PG  - 10-17
LID - S0165-2478(22)00053-0 [pii]
LID - 10.1016/j.imlet.2022.04.004 [doi]
AB  - Circular RNAs (circRNAs) play critical roles in cancer procession, including 
      papillary thyroid cancer (PTC). Despite of published reports regarding the 
      abnormal downregulation of circ_100395 in PTC, the role and regulatory mechanism 
      of which are still undiscovered. Circ_100395 expression was examined via qRT-PCR. 
      Cell growth was detected by the CCK-8 and colony formation, BrdU incorporation 
      and flow cytometry assays. Cell migration and invasion were measured using 
      transwell assays. Aerobic glycolysis was analyzed by the glucose uptake and 
      lactate production. Immunoblotting was performed to evaluate the associated 
      proteins. Decreased circ_100395 expression was shown in PTC tissues and cell 
      lines. Circ_100395 overexpression significantly reduced aerobic glycolysis and 
      the survival, migration and invasion abilities and downregulated 
      phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
      pathway, which were reversed by the PI3K activator 740Y-P. Our data demonstrated 
      that circ_100395 may play an anti-oncogenic role in PTC cells through the 
      inhibition of PI3K/AKT/mTOR signaling pathway.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Chen, LiangDong
AU  - Chen L
AD  - Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, 
      Wuhan 430071, Hubei, China. Electronic address: liangdongchen123@163.com.
FAU - Zhuo, DeQiang
AU  - Zhuo D
AD  - Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, 
      Hubei, China.
FAU - Yuan, HongYin
AU  - Yuan H
AD  - Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, 
      Wuhan 430071, Hubei, China.
LA  - eng
PT  - Journal Article
DEP - 20220418
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (MicroRNAs)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Gene Expression Regulation, Neoplastic
MH  - Glycolysis
MH  - Humans
MH  - *MicroRNAs/metabolism
MH  - Phosphatidylinositol 3-Kinase/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/physiology
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Thyroid Cancer, Papillary/genetics/metabolism/pathology
MH  - *Thyroid Neoplasms/genetics/metabolism/pathology
OTO - NOTNLM
OT  - Circ_100395
OT  - Circular RNA
OT  - Glycolysis
OT  - PI3K/AKT/mTOR
OT  - Papillary thyroid cancer
EDAT- 2022/04/22 06:00
MHDA- 2022/06/03 06:00
CRDT- 2022/04/21 20:11
PHST- 2022/01/30 00:00 [received]
PHST- 2022/04/02 00:00 [revised]
PHST- 2022/04/16 00:00 [accepted]
PHST- 2022/04/22 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/04/21 20:11 [entrez]
AID - S0165-2478(22)00053-0 [pii]
AID - 10.1016/j.imlet.2022.04.004 [doi]
PST - ppublish
SO  - Immunol Lett. 2022 Jun;246:10-17. doi: 10.1016/j.imlet.2022.04.004. Epub 2022 Apr 
      18.